<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107570">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892163</url>
  </required_header>
  <id_info>
    <org_study_id>SIVS1007</org_study_id>
    <nct_id>NCT01892163</nct_id>
  </id_info>
  <brief_title>Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone</brief_title>
  <acronym>OZDRY</acronym>
  <official_title>A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 μg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Wolverhampton Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frimley Park Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Moorfields Eye Hospital NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg
      Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical
      coherence tomography (OCT)-guided PRN dosing in patients with refractory diabetic macular
      edema.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The difference between arms in the change from baseline in best corrected visual acuity at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between arms in change from baseline in each domain and composite scores of the National Eye Institute Visual function questionnaire (VFQ-25).</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between arms in change in central subfield thickness.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ocular and systemic serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex PRN dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ozurdex PRN dosing versus Ozurdex fixed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozurdex fixed dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Dexamethasone implant (Ozurdex)</description>
    <arm_group_label>Ozurdex PRN dosing</arm_group_label>
    <arm_group_label>Ozurdex fixed dosing</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex aged 18 years or over

          2. Diagnosis of diabetes mellitus (type 1 or type 2).

          3. Best corrected visual acuity in the study eye between ≥34 and ≤73 ETDRS letters at 1m
             at baseline attributable to diabetic macular edema (DME)

          4. On clinical exam at baseline in the study eye, retinal thickening due to diabetic
             macular oedema involving the centre of the macula and OCT central subfield &gt; 300
             microns despite previous therapy.

          5. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate
             fundus photographs.

          6. Ability to return for study visits

          7. Visual acuity in fellow eye ≥ 2/60

          8. Ability to give informed consent throughout the duration of the study

        Main Exclusion Criteria:

          1. Macular ischaemia

          2. Macular oedema is considered to be due to a cause other than diabetic macular oedema.

          3. Co-existent ocular disease

          4. An ocular condition is present (other than diabetes) that, in the opinion of the
             investigator,  might affect macular oedema or alter visual acuity during the course
             of the study.

          5. A substantial cataract that, in the opinion of the investigator, is likely to be
             decreasing visual acuity by 3 lines or more.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sobha Sivaprasad, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sobha Sivaprasad, FRCS</last_name>
    <phone>07817886759</phone>
    <email>sobha.sivaprasad@moorfields.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vicky McCudden</last_name>
    <phone>02075662019</phone>
    <email>vicky.mccudden@moorfields.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sobha Sivaprasad, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Moorfields Eye Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Sobha Sivaprasad</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Diabetic macular edema, Ozurdex</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
